Introduction
Background
Berloque dermatitis obtains its name from the German word berlock or the French berloque, meaning trinket or charm. Rosenthal1 coined the term in 1925 to describe pendantlike streaks of pigmentation on the neck, face, arms, or trunk. He suspected they were due to fluid droplets, unaware that Freund2 in 1916 had described hyperpigmented macules due to sun exposure after the application of eau de cologne. The phototoxic ingredient causing the pigmentation proved to be bergapten, a component of oil of bergamot, derived from the rind of Citrus bergamia, the bergamot lime. Several cases were reported in the 1950s and 1960s following increased use of perfumes containing oil of bergamot and the passion for sunbathing. Since the introduction of artificial oil of bergamot and the reduced use of the natural product in perfumes, berloque dermatitis has become rare.
The following related resources may be helpful:
- Medscape Aesthetic Medicine Resource Center
- eMedicine Cosmetics article
- eMedicine Cosmeceuticals article
Pathophysiology
Phototoxicity or photoirritation is a chemically induced nonimmunologic acute skin irritation requiring light (usually within the UVA spectrum, ie, 320-400 nm). The skin response resembles exaggerated sunburn and does not require prior sensitization; it can be caused by a single simultaneous exposure to the chemical and light source. The photoactive chemical may enter the skin via topical administration, or via ingestion, inhalation, or parenteral administration. The reaction can be evoked in all subjects as long as the concentration of the chemical and the dose of light are sufficient.
In the case of berloque dermatitis, the phototoxic reaction is induced by the effect of long-wave ultraviolet (UVA) radiation on bergapten, or 5-methoxypsoralens, a furocoumarin now known to be the only photoactive component of bergamot oil (see Media File 2). The bergapten-UVA radiation combination induces an intensification of melanogenesis and a corresponding increase in the number of functional melanocytes, which are more dendritic and dopa-positive. The distribution of melanosomes in keratinocyte changes from the aggregate to nonaggregate form.
Frequency
United States
The exact incidence of berloque dermatitis is unknown. In the Untied States, berloque dermatitis now is exceedingly rare due to the use of bergapten-free fragrance formulations. The US Hazardous Substances Act issued regulations stating that products containing oil of bergamot must not exceed 62 ppm bergapten, 2% bergamot oil. Following work performed by Marzulli and Maibach3 and reported in 1970, even lower concentrations than this have been recommended (<0.3% bergamot oil, equivalent to 0.001% bergapten), and bergapten-free bergamot oil is used almost always now in the Untied States. However, in some countries where bergamot oil continues to be used, berloque dermatitis remains a problem. Even in the Untied States, milder forms still are being observed. Recently, a patient was reported to have severe berloque dermatitis due to using a suntan booth immediately after applying some 40-year-old Shalimar perfume, which contained bergamot oil.
Apart from the bergamot lime, bergapten also is a component in other substances, inducing bergapten phototoxicity without the typical pendantlike appearance of berloque dermatitis. For instance, in Norway, bergapten phototoxicity has been reported due to Heracleum laciniatum and in Denmark due to Heracleum mantegazzianum (giant hogweed).4,5
Mortality/Morbidity
Phototoxic reactions currently are the most frequently recognized form of photosensitivity reactions. Berloque dermatitis, however, is far more uncommon due to the reasons described above.
Race
Precise information about racial predilection is not available.
Sex
Berloque dermatitis usually occurs in females who wear fragrances containing oil of bergamot, but males who wear fragrances or fragrance-containing products, such as aftershave lotion, also may develop berloque dermatitis.
Age
Berloque dermatitis usually occurs in women, although it can occur in persons of any age who apply fragrances containing oil of bergamot.
Clinical
History
The clinical presentation of berloque dermatitis may be classically divided into 2 phases. The initial acute inflammatory phase consists of erythema, edema, pain, pruritus, and increase in skin temperature around the area of contact with the phototoxic agent. The second stage is hyperpigmentation of the lesion. Patients usually present with small areas of redness or pigmentation of the skin, usually on sun-exposed areas, such as the neck. Pain and, sometimes, pruritus may be felt during the acute erythematous phase before the lesions become hyperpigmented. However, hyperpigmentation is the chief complaint; sometimes patients may not even recall the inflammatory phase. A careful history may reveal use of a perfume or fragrance-containing product on the skin prior to a period of sun exposure, such as sunbathing or a picnic. If untreated, the natural history of the disease also is biphasic; the inflammatory lesions resolve in days to weeks, but the pigmentation may last months or even years.
Physical
Erythema, edema, vesiculation, hyperpigmentation, and desquamation are typical phototoxic skin effects. In classic berloque dermatitis, brown hyperpigmentation with or without preceding erythema is seen in a droplike or pendantlike configuration. It usually is distributed over the sides of the neck in adult females, although it may be seen in any part of the body where perfume was applied followed by sun-exposure.
Some less typical presentations of berloque dermatitis are, for example, symmetrical facial pigmentation on a man, caused by aftershave lotion containing bergapten, and an infant who developed pigmentation on her body and arms where her mother applied eau de toilette prior to taking her to the beach.
Causes
Bergapten, or 5-methoxypsoralen, is the photoactive component of bergamot oil from the bergamot lime (C bergamia), which is a popular ingredient in perfumes and fragrances. Apart from their obvious existence in cosmetics and toiletries (such as toilet water, aftershave lotions, colognes, sunscreen lotions, moisturizers), perfumes also are found in soap, household cleaners, detergents, air fresheners, and a myriad of other everyday items.
Besides the bergamot lime, bergapten is a naturally occurring component of various other fruits and plants (see Media File 3). Examples of these are figs (Ficus carica), celery (Apium graveolens), lemon oil, Tromso palm (H laciniatum), Queen Anne's lace (Ammi majus), and giant Russian hogweed (H mantegazzianum). All these are capable of inducing bergapten phototoxicity, although they are not perfume-related and, therefore, classified as phytophotodermatitis rather than berloque dermatitis.
More on Berloque Dermatitis |
Overview: Berloque Dermatitis |
| Differential Diagnoses & Workup: Berloque Dermatitis |
| Treatment & Medication: Berloque Dermatitis |
| Multimedia: Berloque Dermatitis |
| References |
| Next Page » |
References
Rosenthal O. Berloque dermatitis: Berliner Dermatologische Gesellschaft. Dermatologische Zeitschrift. 1925;42:295.
Freund E. Uber bisher noch nicht bershriebene Kunstlicke hauverfarbungen. Dermatol Wochenschr. 1916;63:931-3.
Marzulli FN, Maibach HI. Perfume phototoxicity. J Soc Cosmetic Chem. 1970;21:695-715.
Kavli G, Raa J, Johnson BE, Volden G, Haugsbø S. Furocoumarins of Heracleum laciniatum: isolation, phototoxicity, absorption and action spectra studies. Contact Dermatitis. Jul 1983;9(4):257-62. [Medline].
Camm E, Buck HW, Mitchell JC. Phytophotodermatitis from Heracleum mantegazzianum. Contact Dermatitis. Apr 1976;2(2):68-72. [Medline].
Zhai H, Wilhelm K, Maibach HI. Photoirritation (phototoxicity/phototoxic dermatitis). In: Dermatotoxicology. 7th ed. Washington, DC: Taylor & Francis; 2008:209-14, 537-46.
Holtz R. REACH and In Vitro Alternatives: Phototoxicity Testing. Cosmet Toilet. May 2008;123:61-3.
Spielmann H, Balls M, Dupuis J, Pape WJ, Pechovitch G, Desilva O, et al. The international EU/COLIPA in vitro phototoxicity validation study - results of phase II (blind trial) - Part 1 - The 3T3 NRU phototoxicity test. Toxicol In Vitro. 1998;12:305-27.
Spielmann H, Lovell WW, Hoelzle E, Johnson BE, Maurer T, Miranda MA, et al. In vitro phototoxicity testing. The report and recommendations of ECVAM workshop 2. Altern Lab Anim. 1994;22:314-48.
Spielmann H, Muller L, Averbeck D, Balls M, Brendler-Schwaab S, Castell JV, et al. The second ECVAM workshop on Phototoxicity Testing - the report and recommendations of ECVAM Workshop 42. Altern Lab Anim. 2000;28:777-814.
Spielmann H, Balls M, Brand M, Doring B, Holzhutter HG, Kalweit S, et al. EEC COLIPA project on in-vitro phototoxicity testing - first results obtained with BALB/C 3T3 cell phototoxicity assay. Toxicol In Vitro. 1994;8:793-6.
Jones PA, King AV. High throughput screening (HTS) for phototoxicity hazard using the in vitro 3T3 neutral red uptake assay. Toxicol In Vitro. Oct-Dec 2003;17(5-6):703-8. [Medline].
Spielmann H, Liebsch M. Validation successes: chemicals. Altern Lab Anim. Dec 2002;30 Suppl 2:33-40. [Medline].
Kejlová K, Jírová D, Bendová H, Kandárová H, Weidenhoffer Z, Kolárová H, et al. Phototoxicity of bergamot oil assessed by in vitro techniques in combination with human patch tests. Toxicol In Vitro. Oct 2007;21(7):1298-303. [Medline].
Hans RK, Agrawal N, Verma K, Misra RB, Ray RS, Farooq M. Assessment of the phototoxic potential of cosmetic products. Food Chem Toxicol. May 2008;46(5):1653-8. [Medline].
Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. Jan 1975;111(1):40-8. [Medline].
American Society of Health-System Pharmacists. Hydroquinone. American Hospital Formulary Service Drug Information. 1998;2971.
Baran R, Maibach HI. Textbook of Cosmetic Dermatology. 3rd ed. London: Taylor and Francis; 2005:65-70.
Castell JV, Gomez-Lechon MJ. In Vitro Methods in Pharmaceutical Research. San Diego, Calif: Academic Press; 1997:290-315.
Harber LC, Bickers D, eds. Photosensitivity Diseases: Principles of Diagnosis & Treatment. Toronto: BC Decker; 1989.
Kamide R, Arase S, Takiwaki, Watanabe S, Watanabe Y, Kageyama S. Clinical evaluation on the effects of XSC-29 preparation on the pigmentation of the skin by exposure to ultraviolet light. Nishinihon J Dermatol. 1995;57:136-42.
Lovell CR. Plants and the Skin. Vol 6. Oxford: Blackwell Scientific Publications; 1993:64-85.
Maibach HI, Marzulli FN. Photoirritation (phototoxicity) from topical agents. Dermatol Clin. Apr 1986;4(2):217-22. [Medline].
Rietschel RL, Fowler JF Jr. Fisher's Contact Dermatitis. Baltimore: Lippincott William & Wilkins; 1995:524-543.
Wilkinson JD, English J. Psoralens. Seminars in Dermatol. June 1983;2(2):85-100.
Zaynoun ST, Aftimos BA, Tenekjian KK, Kurban AK. Berloque dermatitis - a continuing cosmetic problem. Contact Dermatitis. Mar 1981;7(2):111-6. [Medline].
Further Reading
Keywords
berlock dermatitis, perfume phototoxicity, perfume photoirritation, bergapten phototoxicity, bergapten photoirritation, bergamot phototoxicity, bergamot photoirritation, photodermatitis pigmentaria, dermite pigmentée en forme de coulée, 5-Methoxypsoralens photoirritation
Overview: Berloque Dermatitis